Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (SCNxA) with small molecules
First Claim
Patent Images
1. A method of treating a patient having Dravet Syndrome comprising:
- contacting said patient with at least one compound selected from the group consisting of milnacipran, torsemide, pinacidil, benidipine, ketoconazole, ebselen, tadalafil, zeranol, nefazadone, lomerizine, icariin, omeprazole, esomeprazole, 2-[5-[3-(4-Methylsulfonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1H-indol-3-yl]ethanamine, nitrendipine, amlexanox, mosapride, or stanozolol or pharmaceutically acceptable salts, isomers, enantiomers, isoforms, polymorphs, hydrates, solvates thereof wherein said treatment results in the upregulation of the expression of a sodium channel, voltage-gated, alpha subunit (SCN1A) polynucleotide and treats said patient having Dravet Syndrome.
1 Assignment
0 Petitions
Accused Products
Abstract
Small compounds that modulate the expression of and/or function of sodium channel, voltage-gated, alpha subunit (SCNxA) are presented. Pharmaceutical compositions containing such small molecules and their use in treating diseases and disorders associated with the expression of SCNxA are also presented.
209 Citations
2 Claims
-
1. A method of treating a patient having Dravet Syndrome comprising:
contacting said patient with at least one compound selected from the group consisting of milnacipran, torsemide, pinacidil, benidipine, ketoconazole, ebselen, tadalafil, zeranol, nefazadone, lomerizine, icariin, omeprazole, esomeprazole, 2-[5-[3-(4-Methylsulfonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1H-indol-3-yl]ethanamine, nitrendipine, amlexanox, mosapride, or stanozolol or pharmaceutically acceptable salts, isomers, enantiomers, isoforms, polymorphs, hydrates, solvates thereof wherein said treatment results in the upregulation of the expression of a sodium channel, voltage-gated, alpha subunit (SCN1A) polynucleotide and treats said patient having Dravet Syndrome.
-
2. A method of treating a patient having generalized epilepsy with febrile seizure plus (GEFS+) with a therapeutically effective dose of at least one compound selected from the group consisting of milnacipran, torsemide, pinacidil, benidipine, ketoconazole, ebselen, tadalafil, zeranol, nefazadone, lomerizine, icariin, omeprazole, esomeprazole, 2-[5-[3-(4-Methylsulfonylamino)benzyl-1,2,4-oxadiazol-5-yl]-1H-indol-3-yl]ethanamine, nitrendipine, amlexanox, mosapride, or stanozolol or pharmaceutically acceptable salts, isomers, enantiomers, isoforms, polymorphs, hydrates or solvates thereof that upregulates the expression of a sodium channel, voltage-gated, alpha subunit (SCN 1A), and wherein the administration of said compound relieves or causes regression of said disease.
Specification